CL2018003319A1 - Compuestos de mic-1 y usos de estos. - Google Patents
Compuestos de mic-1 y usos de estos.Info
- Publication number
- CL2018003319A1 CL2018003319A1 CL2018003319A CL2018003319A CL2018003319A1 CL 2018003319 A1 CL2018003319 A1 CL 2018003319A1 CL 2018003319 A CL2018003319 A CL 2018003319A CL 2018003319 A CL2018003319 A CL 2018003319A CL 2018003319 A1 CL2018003319 A1 CL 2018003319A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- mic
- amino acid
- refers
- extension
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 102100026436 Regulator of MON1-CCZ1 complex Human genes 0.000 title 1
- 101710180672 Regulator of MON1-CCZ1 complex Proteins 0.000 title 1
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 abstract 3
- 101710194460 Growth/differentiation factor 15 Proteins 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
LA INVENCIÓN SE REFIERE A COMPUESTOS DE MIC-1. MÁS ESPECÍFICAMENTE, SE REFIERE A COMPUESTOS QUE COMPRENDEN UN POLIPÉPTIDO MIC-1 Y UNA EXTENSIÓN DE AMINOÁCIDO EN EL N-TERMINAL, EN DONDE DICHA EXTENSIÓN CONSISTE EN 3 A 36 RESIDUOS DE AMINOÁCIDOS Y DONDE EL COMPUESTO TIENE UN PI CALCULADO INFERIOR A 6.5. LOS COMPUESTOS DE LA INVENCIÓN TIENEN ACTIVIDAD DE MIC-1. LA INVENCIÓN SE REFIERE, ADEMÁS, A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN TALES COMPUESTOS Y EXCIPIENTES FARMACÉUTICAMENTE ACEPTABLES, ASÍ COMO TAMBIÉN AL USO MÉDICO DE LOS COMPUESTOS.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2016083104 | 2016-05-24 | ||
CN2016103574 | 2016-10-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2018003319A1 true CL2018003319A1 (es) | 2019-02-01 |
Family
ID=59009675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018003319A CL2018003319A1 (es) | 2016-05-24 | 2018-11-21 | Compuestos de mic-1 y usos de estos. |
Country Status (18)
Country | Link |
---|---|
US (2) | US20190248852A1 (es) |
EP (1) | EP3463412A1 (es) |
JP (1) | JP7013390B2 (es) |
KR (1) | KR102433503B1 (es) |
CN (1) | CN109414471A (es) |
AU (1) | AU2017269496B2 (es) |
BR (1) | BR112018072034A2 (es) |
CA (1) | CA3025251A1 (es) |
CL (1) | CL2018003319A1 (es) |
CO (1) | CO2018012258A2 (es) |
IL (1) | IL262926A (es) |
MA (1) | MA45113A (es) |
MX (1) | MX2018014023A (es) |
PE (1) | PE20190117A1 (es) |
PH (1) | PH12018502465A1 (es) |
SA (1) | SA518400460B1 (es) |
TW (1) | TW201741333A (es) |
WO (1) | WO2017202936A1 (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10675353B2 (en) | 2016-05-24 | 2020-06-09 | Amgen Inc. | Pegylated carfilzomib compounds |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5977814B2 (ja) | 2011-04-08 | 2016-08-24 | アムジエン・インコーポレーテツド | 増殖分化因子15(gdf−15)を使用して代謝障害を治療または改善する方法 |
MA38873B1 (fr) | 2013-07-31 | 2018-11-30 | Amgen Inc | Constructions contenant le facteur 15 de différentiation de croissance (gdf-15) |
CA3045700A1 (en) | 2016-12-06 | 2018-06-14 | St Vincent's Hospital Sydney Limited | Treatment of obesity and eating disorders |
TWI710377B (zh) * | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Mic-1化合物及其用途 |
PE20201350A1 (es) | 2018-04-09 | 2020-11-30 | Amgen Inc | Proteinas de fusion del factor de diferenciacion de crecimiento 15 |
WO2020031149A2 (en) | 2018-08-10 | 2020-02-13 | Novartis Ag | Gfral extracellular domains and methods of use |
US20230210950A1 (en) | 2019-10-04 | 2023-07-06 | Amgen Inc. | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
EP4085077A4 (en) | 2019-12-31 | 2024-01-17 | Beijing Ql Biopharmaceutical Co Ltd | FUSION PROTEINS FROM GLP-1 AND GDF15 AND CONJUGATES THEREOF |
EP4237438A1 (en) * | 2020-10-27 | 2023-09-06 | Beijing QL Biopharmaceutical Co., Ltd. | Fusion proteins of gdf15 and use thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL114160A (en) * | 1994-06-17 | 2006-12-31 | Novo Nordisk As | Dna constructs encoding heterologous proteins and processes for the heterologous protein production in yeast |
AU3247699A (en) * | 1998-02-17 | 1999-09-06 | Novo Nordisk A/S | Lipase variant |
CA2390820A1 (en) * | 2002-06-17 | 2003-12-17 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
US7858338B2 (en) | 2006-10-13 | 2010-12-28 | Novo Nordisk Health Care Ag | Processing enzymes fused to basic protein tags |
DK2393828T3 (en) * | 2009-02-03 | 2017-01-23 | Amunix Operating Inc | Extended recombinant polypeptides and compositions comprising same |
US8680050B2 (en) * | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
ES2705249T3 (es) * | 2009-06-08 | 2019-03-22 | Amunix Operating Inc | Polipéptidos reguladores de glucosa y métodos para su producción y uso |
WO2013148117A1 (en) * | 2012-03-27 | 2013-10-03 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
JP6696915B2 (ja) * | 2014-06-24 | 2020-05-20 | ノヴォ ノルディスク アー/エス | Mic−1融合タンパク質及びその使用 |
CA2964808C (en) * | 2014-10-30 | 2023-06-27 | Acceleron Pharma Inc. | Methods and compositions using gdf15 polypeptides for increasing red blood cells |
-
2017
- 2017-05-24 MA MA045113A patent/MA45113A/fr unknown
- 2017-05-24 TW TW106117186A patent/TW201741333A/zh unknown
- 2017-05-24 KR KR1020187035810A patent/KR102433503B1/ko active IP Right Grant
- 2017-05-24 MX MX2018014023A patent/MX2018014023A/es unknown
- 2017-05-24 WO PCT/EP2017/062583 patent/WO2017202936A1/en unknown
- 2017-05-24 AU AU2017269496A patent/AU2017269496B2/en not_active Ceased
- 2017-05-24 CN CN201780032204.5A patent/CN109414471A/zh not_active Withdrawn
- 2017-05-24 BR BR112018072034-8A patent/BR112018072034A2/pt not_active Application Discontinuation
- 2017-05-24 PE PE2018002805A patent/PE20190117A1/es unknown
- 2017-05-24 CA CA3025251A patent/CA3025251A1/en not_active Withdrawn
- 2017-05-24 JP JP2018561606A patent/JP7013390B2/ja active Active
- 2017-05-24 US US16/303,516 patent/US20190248852A1/en not_active Abandoned
- 2017-05-24 EP EP17727834.8A patent/EP3463412A1/en active Pending
-
2018
- 2018-11-11 IL IL262926A patent/IL262926A/en unknown
- 2018-11-14 CO CONC2018/0012258A patent/CO2018012258A2/es unknown
- 2018-11-19 SA SA518400460A patent/SA518400460B1/ar unknown
- 2018-11-21 CL CL2018003319A patent/CL2018003319A1/es unknown
- 2018-11-23 PH PH12018502465A patent/PH12018502465A1/en unknown
-
2021
- 2021-03-08 US US17/194,908 patent/US20210198331A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10675353B2 (en) | 2016-05-24 | 2020-06-09 | Amgen Inc. | Pegylated carfilzomib compounds |
Also Published As
Publication number | Publication date |
---|---|
MX2018014023A (es) | 2019-04-04 |
US20230212245A1 (en) | 2023-07-06 |
JP2019520333A (ja) | 2019-07-18 |
KR20190008290A (ko) | 2019-01-23 |
WO2017202936A1 (en) | 2017-11-30 |
MA45113A (fr) | 2019-04-10 |
KR102433503B1 (ko) | 2022-08-18 |
US20210198331A1 (en) | 2021-07-01 |
RU2018141829A (ru) | 2020-06-25 |
AU2017269496A1 (en) | 2018-11-15 |
PE20190117A1 (es) | 2019-01-16 |
IL262926A (en) | 2018-12-31 |
TW201741333A (zh) | 2017-12-01 |
CO2018012258A2 (es) | 2018-11-30 |
JP7013390B2 (ja) | 2022-01-31 |
SA518400460B1 (ar) | 2022-09-21 |
CN109414471A (zh) | 2019-03-01 |
PH12018502465A1 (en) | 2019-04-08 |
EP3463412A1 (en) | 2019-04-10 |
AU2017269496B2 (en) | 2021-03-25 |
BR112018072034A2 (pt) | 2019-02-12 |
CA3025251A1 (en) | 2017-11-30 |
US20190248852A1 (en) | 2019-08-15 |
RU2018141829A3 (es) | 2020-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018003319A1 (es) | Compuestos de mic-1 y usos de estos. | |
CL2019003441A1 (es) | Puestos de mic-1 y usos de estos. | |
MY187047A (en) | Selective pyy compounds and uses thereof | |
CL2017001883A1 (es) | Compuestos antisenescentes y usos de los mismos | |
TW201613958A (en) | MIC-1 fusion proteins and uses thereof | |
CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
CL2016002389A1 (es) | Compuestos derivados de amidopiridina, agonista inverso del receptor cannabinoide tipo 2 composicion farmaceutica procedimiento de preparación y uso de los compuestos en el tratamiento o profilaxis del dolor neuropatico, asma, osteoporosis, inflamacion, entre otros. | |
PH12021550705A1 (en) | Stable semaglutide compositions and uses thereof | |
EA201791696A1 (ru) | Композиция для лечения веноокклюзионной болезни печени | |
AR120721A2 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
CO2020005919A2 (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas | |
BR112015013675A2 (pt) | composições compreendendo vortioxetina e donepezil | |
CL2017003144A1 (es) | Péptidos lipidados resistentes a proteasas | |
BR112015007592A2 (pt) | composições de enalapril | |
EA202091095A1 (ru) | Пероральная доставка пептидных аналогов glp-1 | |
EA201791009A1 (ru) | Композиции, содержащие циклоспорин | |
CL2021000129A1 (es) | Apirasas solubilizadas, métodos y usos | |
WO2017093810A3 (en) | Composition for intraoral delivery of biologically active peptides and proteins | |
EA201591717A1 (ru) | Твердые формы гидрохлорида вемурафениба | |
CL2017003201A1 (es) | Variantes de il-37 | |
EA201691792A1 (ru) | Фармацевтические составы на основе вилдаглиптина | |
EA202191515A1 (ru) | Фармацевтическая композиция, содержащая апиксабан | |
EA201892837A1 (ru) | Физиологически сбалансированные составы для инъекций, включающие фоснетупитант | |
EA201990162A1 (ru) | Фармацевтические композиции | |
CL2019000099A1 (es) | Factor vii de coagulación de larga duración y métodos para producir el mismo. |